MARKET

CGEM

CGEM

Cullinan Oncology Inc
NASDAQ
8.52
-0.20
-2.29%
After Hours: 8.90 +0.38 +4.46% 18:37 03/21 EDT
OPEN
8.64
PREV CLOSE
8.72
HIGH
8.76
LOW
8.44
VOLUME
794.96K
TURNOVER
--
52 WEEK HIGH
30.19
52 WEEK LOW
7.90
MARKET CAP
498.53M
P/E (TTM)
-2.7370
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at CGEM last week (0310-0314)?
Weekly Report · 6d ago
Weekly Report: what happened at CGEM last week (0303-0307)?
Weekly Report · 03/10 09:28
Cullinan Oncology Coverage Assumed by Morgan Stanley at Overweight
Dow Jones · 03/07 17:32
Cullinan Oncology Price Target Cut to $35.00/Share From $38.00 by Morgan Stanley
Dow Jones · 03/07 17:32
Morgan Stanley Assumes Cullinan Therapeutics at Overweight, Lowers Price Target of $35
Benzinga · 03/07 17:22
Cullinan Therapeutics assumed with an Overweight at Morgan Stanley
TipRanks · 03/07 13:21
CULLINAN THERAPEUTICS <CGEM.O>: MORGAN STANLEY CUTS TARGET PRICE TO $35.00 FROM $38.00
Reuters · 03/07 12:44
U.S. RESEARCH ROUNDUP- Adobe, Tesla, Victoria's Secret
Reuters · 03/07 07:04
More
About CGEM
Cullinan Therapeutics, Inc., formerly Cullinan Oncology, Inc., is a biopharmaceutical company focused on developing modality-agnostic targeted therapies. It has a portfolio of clinical-stage assets that inhibit key drivers of disease or harness the immune system to eliminate diseased cells in both oncology and autoimmune diseases. Its pipeline includes CLN-619, CLN-978, Zipalertinib (CLN-081/TAS6417), CLN-049, CLN-418, and CLN-617. Its lead unpartnered program, CLN-619, is a humanized lgG1 monoclonal antibody (mAb) that binds to the stress induced ligands MICA and MICB (MICA/B), which are expressed on a variety of solid tumors and hematologic malignancies. CLN-978 is a novel, highly potent, half-life extended CD19xCD3 bispecific T cell engager construct. CLN-081/TAS6417 is a novel, orally available, covalent inhibitor of mutant epidermal growth factor receptor (EGFR). CLN-049 is a FLT3xCD3 T cell engaging bispecific antibody. CLN-418 is a B7H4 x 4-1BB bispecific immune activator.

Webull offers Cullinan Therapeutics Inc stock information, including NASDAQ: CGEM real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CGEM stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CGEM stock methods without spending real money on the virtual paper trading platform.